Second induction in pediatric patients with recurrent acute lymphoid leukemia using DFCI-ALL protocols

Journal of Pediatric Hematology/Oncology

Volumn 27, Issue 2, 2005, Pages 73-79

  Dalle, Jean Hugues ^a,c   Moghrabi, Albert ^a   Rousseau, Pierre ^b   Leclerc, Jean Marie ^a   Barrette, Stephane ^a   Bernstein, Mark L ^a   Champagne, Josette ^a   David, Michele ^a   Demers, Jocelyn ^a   Duval, Michel ^a   Hume, Heather ^a   Meyer, Patrick ^a   Champagne, Martin A ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

^c La Fondation Charles Bruneau ^*  (United States)

Author keywords

Acute lymphoblastic leukemia; Children; Reinduction therapy; Relapse

Indexed keywords

ASPARAGINASE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; RAZOXANE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CHILD; CLINICAL PROTOCOL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT CANCER; RETREATMENT; SURVIVAL RATE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; CYTARABINE; DOXORUBICIN; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; METHOTREXATE; PREDNISONE; RECURRENCE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 13944255136     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mph.0000152860.97998.32     Document Type: Article

References (30)

1. Tsuchida M, Ikuta K, Hanada R, et al. Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981-1995. Leukemia. 2000;14:2295-2306.
2. Vilmer E, Suciu S, Ferster A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia. 2000;14:2257-2266.
3. Silverman LB, Declerck L, Gelber RD, et al. Results of Dana Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia. 2000;14:2247-2256.
4. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia. 2000;14: 2205-2222.
5. Maloney KW, Shustcr JJ, Murphy S, et al. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. Leukemia. 2000;14:2276-2285.
6. Kamps WA, Veerman AJ, van Wering ER, et al. Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991. Leukemia. 2000;14: 2240-2246.
7. Harms DO, Janka-Schaub GE. Co-operative Study Group for Childhood Acute Lymphoblastic Leukemia (COALL): long- term follow-up of trials 82, 85, 89 and 92. Leukemia. 2000;14:2234-2239.
8. Gustafsson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia. 2000;14:2267-2275.
9. Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia. 2000;14:2223-2233.
10. Conter V, Arico M, Valsecchi MG, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (A1EOP) acute lymphoblastic leukemia studies, 1982-1995. Leukemia. 2000;14:2196-2204.
11. Pui CH, Boyett JM, Rivera GK, et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia. 2000;14:2286-2294.
12. Chessells JM. Relapsed lymphoblastic leukaemia in children: a continuing challenge. Br J Haematol. 1998;102:423-438.
13. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351:145-153.
14. Dalle JH, Duval M, Moghrabi A, et al. Results of an unrelated transplant search strategy using partially HLA-mismatched cord blood as an immediate alternative to HLA-matched bone marrow. Bone Marrow Transplant. 2004;33:605-611.
15. Gaynon PS, Qu RP, Chappell RJ, et al. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse-the Children's Cancer Group experience. Cancer. 1998;82:1387-1395.
16. Wheeler K, Richards S, Bailey C, et al. Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experience. Medical Research Council Working Party on Childhood Leukaemia. Br J Haematol. 1998;101: 94-103.
17. Culbert SJ, Shuster JJ, Land VJ, et al. Remission induction and continuation therapy in children with their first relapse of acute lymphoid leukemia. A Pediatric Oncology Group study. Cancer. 1991;67:37-42.
18. Buchanan GR, Rivera GK, Boyett JM, et al. Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group study. Blood. 1988;72:1286-1292.
19. Abshire TC, Pollock BH, Billett AL, et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood. 2000;96: 1709-1715.
20. Henze G, Fengler R, Hartmann R, et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood. 1991;78:1166-1172.
21. Giona F, Testi AM, Annino L, et al. Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP experience. Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto. Associazione Italiana Ematologia ed Ocologia Pediatrica. Br J Haematol. 1994;86:55-61.
22. Uderzo C, Dini G, Locatelli F, et al. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategics. Haematologica. 2000;85(11 Suppl):47-53.
23. Lawson SE, Harrison G, Richards S, et al. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study. Br J Haematol. 2000;108: 531-543.
24. Klumper E, Pieters R, Veerman AJ, et al. in vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood. 1995;86:3861-3868.
25. Klumper E, Pieters R, den Boer ML, et al. in vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia. Br J Cancer. 1995;71:1188-1193.
26. Rivera GK, Hudson MM, Liu Q, et al. Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia. Blood. 1996;88:831-837.
27. Shuper A, Stark B, Kornreich L, et al. Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity. J Child Neurol. 2000;15:573-580.
28. Schroeder H, Garwicz S, Kristinsson J, et al. Outcome after first relapse in children with acute lymphoblastic leukemia: a population-based study of 315 patients from the Nordic Society of Pediatric Hematology and Oncology (NOPHO). Med Pediatr Oncol. 1995;25:372-378.
29. Uderzo C, Balduzzi A. Allogeneic bone marrow transplantation versus chemotherapy in childhood very high risk acute lymphoblastic leukemia in first complete remission: a controversial issue. Haematologica. 2002;87 (8 Suppl):47-50.
30. Uderzo C. Indications and role of allogeneic bone marrow transplantation in childhood very high risk acute lymphoblastic leukemia in first complete remission. Haematologica. 2000;85(11 Suppl):9-11.